Welcome to our dedicated page for Neurometrix news (Ticker: NURO), a resource for investors and traders seeking the latest updates and insights on Neurometrix stock.
NeuroMetrix Inc (NURO) is a pioneer in wearable neuromodulation and diagnostic technologies for chronic pain and diabetic neuropathy. This news hub provides investors and healthcare professionals with timely updates on the company's advancements in bioelectrical medicine, regulatory milestones, and strategic initiatives.
Discover official press releases covering product launches, clinical study results, and financial performance. Our curated collection includes updates on NURO's Quell® wearable therapy platform, DPNCheck® diagnostic devices, and innovations in digital health integration. The page serves as a comprehensive resource for understanding the company's progress in addressing chronic conditions through non-invasive solutions.
Key content areas include earnings announcements, FDA regulatory updates, partnership developments, and research breakthroughs. All materials are sourced directly from company filings and verified industry publications to ensure accuracy. Bookmark this page for streamlined access to NeuroMetrix's latest developments in neurostimulation technology and diagnostic screening tools.
NeuroMetrix, Inc. (Nasdaq: NURO) will showcase Quell Fibromyalgia at the American Academy of Pain Medicine's 39th Annual Meeting from March 23-26, 2023, in Ft. Lauderdale, FL. The company will also present two scientific posters on new data related to Quell's effectiveness in treating fibromyalgia, which affects up to 15 million adults in the U.S. Quell is the only FDA-authorized device designed to alleviate fibromyalgia symptoms. Key findings from studies suggest Quell may improve balance and treatment response among patients without weather sensitivity.
NeuroMetrix (NURO) reported Q4 2022 revenues of $1.8 million, up 1.5% YoY, driven by an 18.1% rise in DPNCheck® sales. Gross profit fell 1% to $1.2 million, with a gross margin of 66.6%. Operating expenses decreased to $2.1 million from $2.2 million, though R&D costs dropped due to increased personnel spending. The net loss improved to $0.7 million ($0.09 per share) from $1 million ($0.15 per share) in Q4 2021. For the full year, total revenues reached $8.3 million, with a net loss of $4.4 million compared to $2.3 million last year. Major product launches included Quell Fibromyalgia and DPNCheck 2.0, signaling a strategic shift toward commercialization.
NeuroMetrix, Inc. (NASDAQ: NURO) will announce its 2022 fourth quarter and year-end financial results before the market opens on February 23, 2023. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss these results and relevant business developments. Participants can register in advance for the earnings call and will receive dial-in details. NeuroMetrix focuses on innovative medical devices aimed at improving health outcomes for neurological disorders and pain syndromes, including products like DPNCheck®, ADVANCE®, and Quell® Fibromyalgia.
NeuroMetrix announces the launch of DPNCheck 2.0, a point-of-care device designed to detect peripheral neuropathy. This innovative device uses advanced nerve conduction technology for quick screening and offers a user-friendly touchscreen interface with improved features. Notably, peripheral neuropathy affects up to 30% of the Medicare-aged population, prompting healthcare providers to focus on early detection to prevent severe complications like foot ulcers. DPNCheck 2.0 will be showcased at the Medicare Advantage Leadership Innovations National Conference on January 24-25, 2023.
NeuroMetrix, Inc. (Nasdaq: NURO) will present its innovative device, Quell Fibromyalgia, at the ACR Convergence 2022 from November 12 to 14 in Philadelphia. This wearable neuromodulation technology is the first FDA-authorized device aimed at alleviating fibromyalgia symptoms. Fibromyalgia affects approximately 5 to 15 million U.S. adults, characterized by chronic pain and fatigue. Quell Fibromyalgia, part of NeuroMetrix's prescription wearable neurotherapeutics, supports patients with high pain sensitivity, offering a potential breakthrough in treatment options.
NeuroMetrix (Nasdaq: NURO) has launched the Quell® Fibromyalgia device through its Pathfinder Program. This device is the first FDA-authorized medical device aimed at alleviating fibromyalgia symptoms. The Pathfinder Program, beginning December 1, 2022, will involve 25 key-opinion leaders in fibromyalgia to refine its commercial approach ahead of a full launch expected in Q2 2023. Quell Fibromyalgia utilizes TENS technology and is designed for adults with high pain sensitivity, offering a non-invasive treatment option.
NeuroMetrix (NURO) reported Q3 2022 revenues of $2.0 million, a decline of 4.7% from Q3 2021. DPNCheck® sales fell by 6% due to reduced international orders. Gross profit decreased to $1.3 million, with a margin rate dropping to 64.8%.
Operating expenses rose to $3.0 million, leading to a net loss of $1.6 million ($0.23 per share). The company is preparing for a Q4 2022 launch of Quell Fibromyalgia, the first FDA-authorized device for this condition.
NeuroMetrix (Nasdaq: NURO) will release its 2022 Q3 financial results on Oct 20, 2022, before market opening. A conference call will occur at 8:00 a.m. ET on the same day to discuss these results and other business developments. Participants can register in advance to join the call and ask questions. The company's focus is on enhancing health through innovative medical devices targeting neurological disorders. Its product line includes DPNCheck®, ADVANCE®, and Quell® Fibromyalgia, addressing various health concerns.
